# Sanofi

French pharma leader — Dupixent biologic blockbuster and Warp Speed vaccine contributor; major biologics manufacturing footprint across France, Germany, and US.

Source: https://en.bioecon.ru/companies/sanofi/
Updated: 2026-06-19

- Country: France
- Revenue: €41.6B
- Employees: ~90,000 emp

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | Sanofi intends to invest at least $20 billion in the US through 2030. (2025-05-14) | https://www.prnewswire.com/news-releases/sanofi-to-invest-at-least-20-billion-in-the-us-through-2030-growing-investments-in-science-and-expanding-domestic-manufacturing-302455566.html |
| Production site | Sanofi operates 7 specialty care sites, 10 vaccine sites, and 23 general medicines sites globally. (2025-03-20) | https://www.bioprocessintl.com/upstream-downstream-processing/adding-context-data-mapping-key-to-sanofi-s-digitization-strategy |
| Capacity | Global manufacturing network produces 2 billion doses annually; US operations deliver over 600 million units annually. (2026-08-31) | https://www.sanofi.com/en/our-science/manufacturing-and-supply, https://www.sanofi.us/en/our-science/manufacturing-and-supply |
| Certification | The Neuville-sur-Saône facility is designed to meet LEED certification standards. (2024-05-13) | https://www.sanofi.com/assets/dotcom/pressreleases/2024/2024-05-13-05-00-00-2880074-en.pdf |
| Regulatory approval | Sanofi received ten regulatory approvals across immunology, rare diseases, and other areas in 2025. (2025-12-31) | https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm |

Independent sources: bioprocessintl.com, prnewswire.com, sec.gov

## Technologies

- [Biologics](https://en.bioecon.ru/technology/biologics/)
- [Biopharmaceuticals & biomedicines](https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/)
- [Xenobiology & expanded genetic alphabet (XNA)](https://en.bioecon.ru/technology/xenobiology-expanded-genetic-alphabet/)